Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112337 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL113051 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL113052 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3051429 | 0.88 | KDM4E (0.50) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3051431 | 0.88 | KDM4E (0.50) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL10618828 | 0.87 | KDM4E (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL112449 | 0.86 | KDM4E (0.49) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL111288 | 0.86 | KDM4E (0.49) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL112448 | 0.86 | KDM4E (0.49) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL111289 | 0.86 | KDM4E (0.49) | SMN1; SMN2KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | claimed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024215786-A2 | COMPOSITIONS AND METHODS FOR IMPROVING AUTOPHAGY ACTIVITY AND INHIBITING DYSFUNCTION | WARRIOR ESSENTIALS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | claimed |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | claimed |
| EP-4054553-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | Retina Foundation of the Southwest (US) | 2022-09-14 | — | — | EP | claimed |
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | claimed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024215786-A2 | COMPOSITIONS AND METHODS FOR IMPROVING AUTOPHAGY ACTIVITY AND INHIBITING DYSFUNCTION | WARRIOR ESSENTIALS, LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12011496-B2 | Topical macqui berry formulation | Tracie Martyn International, Inc. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006026713-A2 | TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060045896-A1 | Topical compositions comprising benfotiamine and pyridoxamine | TRACIE MARTYN INTERNATIONAL, LLC | 2006-03-02 | — | — | US | disclosed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | SMN1; SMN2 4541/4885KDM4E 2170/4885MAPT 2515/4885 |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | PDE6C, STRA6, PDE6A | SMN1; SMN2 2532/4885KDM4E 3217/4885MAPT 2605/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | SMN1; SMN2 1808/4885KDM4E 2265/4885MAPT 2476/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | SMN1; SMN2 820/4885KDM4E 3045/4885MAPT 3440/4885 |
| US-20060045896-A1 | Topical compositions comprising benfotiamine and pyridoxamine | AGER, LPO, LOX | SMN1; SMN2 4425/4885KDM4E 1183/4885MAPT 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.